Abstract:Cancer immunotherapy has become a research hotspot in recent years. A variety of targets were developed for small molecule immuno-oncology agents, including retinoic acid-related orphan receptor gamma t (RORγt), chemokine receptor, stimulator of interferon genes (Sting), indoleamine 2,3-dioxygenase (IDO), toll-like receptors (TLR), etc. Among them, the retinoic acid receptor-related orphan receptor γt (RORγt) has gradually attracted more attention in these years. In particular, LYC-55716 (cintirorgon), a small molecule RORγt agonist developed by Lycera, has entered the phase II clinical study. In this work, starting from compound 7, compound 28 was obtained after 4 rounds of compound design, synthesis and SAR studies, which had an EC50 of 0.021 ± 0.002 μM in dual Fluorescence Resonance Energy Transfer (dual-FRET) assay and an EC50 of 0.021 ± 0.002 μM in mouse Th17 cell differentiation assay. It indicated that compound 28 had excellent RORγt agonistic activity and was expected to be developed as a new type of small molecule drug for cancer immunotherapy. The molecular dynamic simulation revealed that the agonist 28 formed a strong HYF triplet intramolecular interaction to stabilize H12, which helped RORγt to form the protein-binding site and therefore made the receptor ready to recruit coactivator. When the inverse agonist s27 bound with RORγt, the steric hindrance between s27 and H479 caused the destruction of the HYF triplet, leading to the collapse of H12, thus the transcription function of RORγt was interrupted due to the failure of recruiting a coactivator molecule. The triplet HYF in RORγt and the rigidity of 28 and s27 were identified to be the structural determinants for the functional switch of RORγt.

Discovery of Novel N -Sulfonamide-tetrahydroquinolines as Potent Retinoic Acid Receptor-Related Orphan Receptor γt (RORγt) Inverse Agonists for the Treatment of Psoriasis

Discovery of novel and potent sulfonamide derivatives as orally available drug for psoriasis

Discovery of 2H-Chromone-4-one Based Sulfonamide Derivatives As Potent Retinoic Acid Receptor-Related Orphan Receptor Γt Inverse Agonists.

Discovery of novel triazine derivatives as potent retinoic acid receptor-related orphan receptor γt (RORγt) inverse agonists

Discovery of Chromane-6-Sulfonamide Derivative As a Potent, Selective, and Orally Available Novel Retinoic Acid Receptor-Related Orphan Receptor Γt Inverse Agonist.

Discovery of Novel N-sulfonamide-tetrahydroisoquinolines As Potent Retinoic Acid Receptor-Related Orphan Receptor Γt Agonists

Discovery and Structural Optimization of 4-(4-(benzyloxy)phenyl)-3,4-dihydropyrimidin-2(1h)-ones As RORc Inverse Agonists

Discovery of N-(2-benzyl-4-oxochroman-7-yl)-2-(5-(ethylsulfonyl) Pyridin-2-yl) Acetamide (b12) As a Potent, Selective, and Orally Available Novel Retinoic Acid Receptor-Related Orphan Receptor Γt Inverse Agonist.

Discovery of Novel N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides As Potent RORγt Inhibitors

Identification of N-phenyl-2-(N-phenylphenylsulfonamido)acetamides as new RORγ inverse agonists: Virtual screening, structure-based optimization, and biological evaluation.

Discovery of N -(4-aryl-5-aryloxy-thiazol-2-yl)-amides as potent RORγt inverse agonists

Discovery of tetrahydroquinolines and benzomorpholines as novel potent RORt agonists

Discovery of Biaryl Amide Derivatives As Potent, Selective, and Orally Bioavailable RORγt Agonists for Cancer Immunotherapy.

Discovery of Aryl-Substituted Indole and Indoline Derivatives As RORγt Agonists

Discovery of N-indanyl Benzamides As Potent RORγt Inverse Agonists

3D-QSAR, molecular docking and molecular dynamics studies of a series of RORγt inhibitors.

Discovery of Tetrahydroquinolines and Benzomorpholines As Novel Potent Ror Gamma T Agonists

Discovery of tetrahydroquinolines and benzomorpholines as novel potent RORγt agonists.

Design, Synthesis, and Biological Activity of Novel Quinone Derivatives as Potent STAT3 Inhibitors for Psoriasis Treatment

Discovery and Optimization of N -Acyl-6-sulfonamide-tetrahydroquinoline Derivatives as Novel Non-Steroidal Selective Glucocorticoid Receptor Modulators

Discovery of <i>tert</i>-amine-based RORt agonists